Attiq A, Afzal S, Wahab H, Ahmad W, Kandeel M, Almofti Y
Drug Des Devel Ther. 2024; 18:4215-4240.
PMID: 39319193
PMC: 11421457.
DOI: 10.2147/DDDT.S475005.
Jamir E, Sarma H, Priyadarsinee L, Kiewhuo K, Nagamani S, Sastry G
PLoS One. 2023; 18(8):e0289890.
PMID: 37556478
PMC: 10411734.
DOI: 10.1371/journal.pone.0289890.
Kumar S, Basu M, Ghosh P, Pal U, Ghosh M
Genes Dis. 2023; 10(4):1402-1428.
PMID: 37334160
PMC: 10079314.
DOI: 10.1016/j.gendis.2022.12.019.
Wasan H, Singh D, Reeta K, Gupta P, Gupta Y
Indian J Pharmacol. 2022; 54(5):364-372.
PMID: 36537406
PMC: 9846916.
DOI: 10.4103/ijp.ijp_318_22.
Li Y, Tang X
Front Immunol. 2021; 12:701443.
PMID: 34650550
PMC: 8505958.
DOI: 10.3389/fimmu.2021.701443.
Inflammatory Mechanism and Clinical Implication of Asthma in COVID-19.
Wisnu Wardana V, Rosyid A
Clin Med Insights Circ Respir Pulm Med. 2021; 15:11795484211042711.
PMID: 34594145
PMC: 8477697.
DOI: 10.1177/11795484211042711.
Recent advances and developments in COVID-19 in the context of allergic diseases.
Ding M, Dong X, Sun Y, Sokolowska M, Akdis M, Veen W
Clin Transl Allergy. 2021; 11(7):e12065.
PMID: 34582102
PMC: 8646609.
DOI: 10.1002/clt2.12065.
Repurposing Vandetanib plus Everolimus for the Treatment of -Mutant Diffuse Intrinsic Pontine Glioma.
Carvalho D, Richardson P, Olaciregui N, Stankunaite R, Lavarino C, Molinari V
Cancer Discov. 2021; 12(2):416-431.
PMID: 34551970
PMC: 7612365.
DOI: 10.1158/2159-8290.CD-20-1201.
Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges.
Hakim A, Hasan M, Hasan M, Lokman S, Azim K, Raihan T
Front Microbiol. 2021; 12:637554.
PMID: 34512561
PMC: 8424194.
DOI: 10.3389/fmicb.2021.637554.
How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility.
Massalska M, Gober H
Front Immunol. 2021; 12:646894.
PMID: 34177895
PMC: 8226076.
DOI: 10.3389/fimmu.2021.646894.
Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges.
Ali F, Mohammedsaleh Z, Ali M, Ghogar O
World J Gastroenterol. 2021; 27(15):1531-1552.
PMID: 33958841
PMC: 8058655.
DOI: 10.3748/wjg.v27.i15.1531.
Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm.
Rabaan A, Al-Ahmed S, Muhammad J, Khan A, Sule A, Tirupathi R
Vaccines (Basel). 2021; 9(5).
PMID: 33946736
PMC: 8145892.
DOI: 10.3390/vaccines9050436.
Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.
Kumar D, Trivedi N
Biomed Pharmacother. 2021; 139:111642.
PMID: 33940506
PMC: 8078916.
DOI: 10.1016/j.biopha.2021.111642.
Experimental therapies under investigation for COVID-19.
Golamari R, Kapoor N, Devaraj T, Sahu N, Kramer C, Jain R
J Community Hosp Intern Med Perspect. 2021; 11(2):187-193.
PMID: 33889318
PMC: 8043541.
DOI: 10.1080/20009666.2021.1874093.
Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality.
Que Y, Hu C, Wan K, Hu P, Wang R, Luo J
Int Rev Immunol. 2021; 41(2):217-230.
PMID: 33616462
PMC: 7919105.
DOI: 10.1080/08830185.2021.1884248.
Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications.
Kumar R, Sharma A, Srivastava J, Siddiqui M, Uddin M, Aleya L
Environ Sci Pollut Res Int. 2021; 28(30):40431-40444.
PMID: 33447984
PMC: 7808930.
DOI: 10.1007/s11356-020-12200-1.
Experimental Pharmacotherapy for COVID-19: The Latest Advances.
Pagliano P, Scarpati G, Sellitto C, Conti V, Spera A, Ascione T
J Exp Pharmacol. 2021; 13:1-13.
PMID: 33442304
PMC: 7800714.
DOI: 10.2147/JEP.S255209.
Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics.
Murphy M, Clay G, Danziger-Isakov L, Schulert G, Paulsen G
Curr Opin Pediatr. 2021; 33(1):129-135.
PMID: 33394741
PMC: 7861135.
DOI: 10.1097/MOP.0000000000000983.
The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.
Choudhary S, Sharma K, Silakari O
Microb Pathog. 2020; 150:104673.
PMID: 33278517
PMC: 7709793.
DOI: 10.1016/j.micpath.2020.104673.
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
Stebbing J, Sanchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S
Sci Adv. 2020; 7(1).
PMID: 33187978
PMC: 7775747.
DOI: 10.1126/sciadv.abe4724.
